Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 87 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Surfactant Clear all
Recruiting Not applicable Interventional

Comparing Surfactant Administration Through Supraglottic Airway and Thin Catheter for Preterm Infants

NCT07030270
View directory record Official record
Conditions
Surfactant, Respiratory Distress Syndrome (Neonatal)
Interventions
Surfactant Administration through Laryngeal or Supraglottic Airway, Surfactant Administration through Thin Catheter
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 72 Hours
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Little Lungs Study

NCT06855043
View directory record Official record
Conditions
Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Interventions
Calfactant, Budesonide
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
7 Days to 14 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

NCT04613206
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Analysis of the Effect of Antimicrobial Soap on Bacterial Survival

NCT02012348
View directory record Official record
Conditions
Survival of Bacteria on Skin After Using Different Soaps
Interventions
Antibacterial soap with triclocarban, Antibacterial soap + benzalkonium chloride, Control soap
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 21, 2026, 7:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epidemiology of Surfactant Protein-B Deficiency

NCT00014859
View directory record Official record
Conditions
Lung Diseases, Respiratory Distress Syndrome, Newborn, Pulmonary Surfactant, Lung Diseases, Interstitial
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 1 Year
Enrollment
5,176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 21, 2026, 7:43 AM EDT
Recruiting Phase 4 Interventional

Non Inferiority Trial Investigating Surfactants Administered Via MIST

NCT06074380
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
MIST surfactant
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
Up to 48 Hours
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Phase 1Phase 2 Interventional

Delivery Room CPAP in Extremely Low Birth Weight Infants

NCT01223274
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia, Continuous Positive Airway Pressure
Interventions
CPAP/PEEP, Standard management practices
Device
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 10 Minutes
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
6
States / cities
Birmingham, Alabama • San Diego, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Terminated Phase 2 Interventional Results available

Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)

NCT04502433
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
CUROSURF® (poractant alfa)
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 23, 2023 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

NCT03969992
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infant
Interventions
AeroFact, nCPAP
Drug · Other
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
26 Weeks to 31 Weeks
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
37
States / cities
Little Rock, Arkansas • Berkeley, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 21, 2026, 7:43 AM EDT
Terminated Phase 4 Interventional Results available

Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome

NCT02164734
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Endotracheal intubation, Laryngeal mask airway, remifentanil
Device · Drug
Lead sponsor
Albany Medical College
Other
Eligibility
2 Hours to 48 Hours
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

NCT03058666
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Aerosolized Calfactant, Solarys
Drug · Device
Lead sponsor
ONY
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Mobile, Alabama • Phoenix, Arizona • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 21, 2026, 7:43 AM EDT
Recruiting Phase 1Phase 2 Interventional

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

NCT04752722
View directory record Official record
Conditions
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
Interventions
EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
Drug
Lead sponsor
enGene, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
50
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Completed No phase listed Observational

Genetic Regulation of Surfactant Deficiency

NCT00828243
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Nutrient
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day to 6 Months
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 21, 2026, 7:43 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial

NCT02907593
View directory record Official record
Conditions
Bronchopulmonary Dysplasia (BPD)
Interventions
Budesonide in Calfactant
Drug
Lead sponsor
Cynthia McEvoy
Other
Eligibility
3 Days to 14 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
San Francisco, California • Jacksonville, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 21, 2026, 7:43 AM EDT
Terminated Phase 1 Interventional

A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

NCT04659122
View directory record Official record
Conditions
COVID-19, Undefined
Interventions
AT-100
Biological
Lead sponsor
Airway Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 21, 2026, 7:43 AM EDT
Recruiting Not applicable Interventional

Video vs. Direct Laryngoscopy for Less Invasive Surfactant Administration

NCT07426016
View directory record Official record
Conditions
Respiratory Distress Syndrome (Neonatal), Surfactant Deficiency Syndrome Neonatal
Interventions
Video Laryngoscopy, Direct Laryngoscopy
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 3 Days
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Phase 2 Interventional Results available

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

NCT02452476
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
CHF5633, Poractant alfa
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 21, 2026, 7:43 AM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

NCT05215327
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
16 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Terminated Phase 1 Interventional

Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04

NCT03748173
View directory record Official record
Conditions
Bronchiolitis
Interventions
Aerosolized Infasurf
Combination Product
Lead sponsor
ONY
Industry
Eligibility
0 Months to 4 Months
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 21, 2026, 7:43 AM EDT
Recruiting No phase listed Observational

A National Registry For Pulmonary Alveolar Proteinosis

NCT02461615
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Phase 4 Interventional Results available

Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation

NCT01939145
View directory record Official record
Conditions
Wound Infection
Interventions
Normal saline, Prontosan
Drug · Device
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 21, 2026, 7:43 AM EDT
Completed Phase 3 Interventional Results available

Trial of Late Surfactant to Prevent BPD: A Pilot Study in Ventilated Preterm Neonates Receiving Inhaled Nitric Oxide

NCT00569530
View directory record Official record
Conditions
Respiratory Distress Syndrome of Prematurity (Surfactant Dysfunction), Bronchopulmonary Dysplasia
Interventions
Infasurf (ONY Inc.), Sham
Drug
Lead sponsor
Roberta Ballard
Other
Eligibility
7 Days to 14 Days
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Berkeley, California • Oakland, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 21, 2026, 7:43 AM EDT
Terminated Phase 3 Interventional Results available

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

NCT00004500
View directory record Official record
Conditions
Meconium Aspiration
Interventions
Lucinactant, Standard Care
Drug · Other
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
Up to 48 Hours
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Warrington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 21, 2026, 7:43 AM EDT
Terminated Phase 3 Interventional Results available

A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration

NCT02772081
View directory record Official record
Conditions
Respiratory Distress Syndrome (RDS)
Interventions
LISA combination product (Curosurf+catheter CHF6440), Curosurf through conventional administration (endotracheal tube)
Combination Product · Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
30 Minutes to 24 Hours
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 21, 2026, 7:43 AM EDT